Skip to content
Mupirocin
Bactroban, Centany (mupirocin) is a small molecule pharmaceutical. Mupirocin was first approved as Bactroban on 1987-12-31. It is used to treat bacterial infections and impetigo in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Centany (generic drugs available since 2003-11-07, discontinued: Bactroban)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mupirocin
Tradename
Company
Number
Date
Products
CENTANYPadagisN-050788 RX2002-12-04
1 products
Show 1 discontinued
Mupirocin calcium
Tradename
Company
Number
Date
Products
BACTROBANGSKN-050703 DISCN1995-09-18
1 products, RLD
BACTROBANGSKN-050746 DISCN1997-12-11
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bactrobanNew Drug Application2012-10-24
centany2007-02-13
mupirocinANDA2023-06-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bacterial infectionsD001424A49
impetigoEFO_1000714D007169L01
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
D06: Antibiotics and chemotherapeutics for dermatological use
D06A: Antibiotics for topical use
D06AX: Other antibiotics for topical use in atc
D06AX09: Mupirocin
R: Respiratory system drugs
R01: Nasal preparations
R01A: Decongestants and other nasal preparations for topical use
R01AX: Other nasal preparations in atc
R01AX06: Mupirocin
HCPCS
No data
Clinical
Clinical Trials
62 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Staphylococcus aureusD013211NCBITaxon_1280459
Surgical wound infectionD0135301348
Staphylococcal infectionsD013203A49.011517
Methicillin-resistant staphylococcus aureusD0556241236
Staphylococcal skin infectionsD013207EFO_1001849L00134
MicrobiotaD06430722
Chronic kidney failureD007676EFO_0003884N18.622
Hiv infectionsD015658EFO_0000764B20112
Orthopedic proceduresD01963711
Bacterial infectionsD001424A4911
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ImpetigoD007169EFO_1000714L0111114
RadiodermatitisD011855L58111
Hereditary hemorrhagic telangiectasiaD013683I78.011
EpistaxisD004844EFO_0003895R04.011
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8433
StaphylococcusD01321011
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AbscessD000038EFO_000303044
FurunculosisD005667L02.9233
Musculoskeletal diseasesD00914011
Inflammatory bowel diseasesD015212EFO_000376711
Digestive system diseasesD004066EFO_0000405K92.911
Cesarean sectionD00258511
EndophthalmitisD00987711
Community-acquired infectionsD01771411
FolliculitisD00549911
CellulitisD002481EFO_0003035L03.9011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMUPIROCIN
INNmupirocin
Description
Mupirocin is an alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections. It has a role as a bacterial metabolite, an antibacterial drug and a protein synthesis inhibitor. It is a monocarboxylic acid, a member of oxanes, an epoxide, a secondary alcohol, a triol and an alpha,beta-unsaturated carboxylic ester. It is a conjugate acid of a mupirocin(1-).
Classification
Small molecule
Drug classt-RNA synthetase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O
Identifiers
PDB
CAS-ID12650-69-0
RxCUI42372
ChEMBL IDCHEMBL719
ChEBI ID7025
PubChem CID446596
DrugBankDB00410
UNII IDD0GX863OA5 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,822 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
51,293 adverse events reported
View more details